ACCESSIBILITY

24/7

Headlines

16:11

Sheryl Sandberg's harrowing documentary exposes Hamas sex crimes

17:56

Mobileye first quarter revenue falls by almost 50% as clients cut back on spending to clear excess stock

14:00

Melio names Boaz BenDavid as its first Chief Financial Officer

13:28

Check Point registers higher than expected Q1 profit helped by growth of AI-powered security platform

Buzz

Most popular

Daily

Weekly

Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale

Nvidia continues Israel shopping spree with acquisition of Deci

Nvidia announces $700 million acquisition of Run:ai

Nvidia on verge of completing $700 million acquisition of Run:ai

Nagomi Security raises $23 million Series A for proactive defense platform

More news

Generic Drugs

12 stories about Generic Drugs

Teva Investors Are Back on the Rollercoaster

27.09.18|Lilach Baumer

The stock of Teva Pharmaceutical Industries Ltd. fell over 11% on NYSE between September 20 and Thursday, bringing a halt to a nearly two weeks rally

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer

Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich

In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer

The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday

אינפו טבע מחירי תרופות גנריות Teva generic drug prices

The Crucial Piece of Information Teva Overlooked

24.12.17|Sophie Shulman

When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich

A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich

Mylan is currently the highest valued company on the TASE at $18.5 billion

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer

Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist

The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016